European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society

Diego Garcia-Borreguero; Luigi Ferini-Strambi; Ralf Kohnen; Shaun O'Keeffe; Claudia Trenkwalder; Birgit Högl; Heike Benes; Poul Jennum; Markku Partinen; Danyal Fer; Pasquale Montagna; Claudio L Bassetti; Alex Iranzo; Karel Sonka; Anne-Marie Williams

doi:10.1111/j.1468-1331.2012.03853.x

European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society

Diego Garcia-Borreguero, Luigi Ferini-Strambi, Ralf Kohnen, Shaun O'Keeffe, Claudia Trenkwalder, Birgit Högl, Heike Benes, Poul Jennum, Markku Partinen, Danyal Fer, Pasquale Montagna, Claudio L Bassetti, Alex Iranzo, Karel Sonka, Anne-Marie Williams

109 Citationer (Scopus)

Abstract

Background: Since the publication of the first European Federation of Neurological Societies (EFNS) guidelines in 2005 on the management of restless legs syndrome (RLS; also known as Willis-Ekbom disease), there have been major therapeutic advances in the field. Furthermore, the management of RLS is now a part of routine neurological practice in Europe. New drugs have also become available, and further randomized controlled trials have been undertaken. These guidelines were undertaken by the EFNS in collaboration with the European Neurological Society and the European Sleep Research Society. Objectives: To provide an evidence-based update of new treatments published since 2005 for the management of RLS. Methods: First, we determined what the objectives of management of primary and secondary RLS should be. We developed the search strategy and conducted a review of the scientific literature up to 31 December 2011 (print and electronic publications) for the drug classes and interventions employed in RLS treatment. Previous guidelines were consulted. All trials were analysed according to class of evidence, and recommendations made according to the 2004 EFNS criteria for rating. Recommendations: Level A recommendations can be made for rotigotine, ropinirole, pramipexole, gabapentin enacarbil, gabapentin and pregabalin, which are all considered effective for the short-term treatment for RLS. However, for the long-term treatment for RLS, rotigotine is considered effective, gabapentin enacarbil is probably effective, and ropinirole, pramipexole and gabapentin are considered possibly effective. Cabergoline has according to our criteria a level A recommendation, but the taskforce cannot recommend this drug because of its serious adverse events.

Originalsprog	Engelsk
Tidsskrift	European Journal of Neurology
Vol/bind	19
Udgave nummer	11
Sider (fra-til)	1385-96
Antal sider	12
ISSN	1351-5101
DOI	https://doi.org/10.1111/j.1468-1331.2012.03853.x
Status	Udgivet - nov. 2012

Adgang til dokumentet

10.1111/j.1468-1331.2012.03853.x

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1468-1331.2012.03853.x

Fingeraftryk

Dyk ned i forskningsemnerne om 'European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Garcia-Borreguero, D., Ferini-Strambi, L., Kohnen, R., O'Keeffe, S., Trenkwalder, C., Högl, B., Benes, H., Jennum, P., Partinen, M., Fer, D., Montagna, P., Bassetti, C. L., Iranzo, A., Sonka, K., & Williams, A-M. (2012). European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. European Journal of Neurology, 19(11), 1385-96. https://doi.org/10.1111/j.1468-1331.2012.03853.x

European guidelines on management of restless legs syndrome : report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. / Garcia-Borreguero, Diego; Ferini-Strambi, Luigi; Kohnen, Ralf et al.

I: European Journal of Neurology, Bind 19, Nr. 11, 11.2012, s. 1385-96.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Garcia-Borreguero, D, Ferini-Strambi, L, Kohnen, R, O'Keeffe, S, Trenkwalder, C, Högl, B, Benes, H, Jennum, P, Partinen, M, Fer, D, Montagna, P, Bassetti, CL, Iranzo, A, Sonka, K & Williams, A-M 2012, 'European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society', European Journal of Neurology, bind 19, nr. 11, s. 1385-96. https://doi.org/10.1111/j.1468-1331.2012.03853.x

Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, O'Keeffe S, Trenkwalder C, Högl B et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. European Journal of Neurology. 2012 nov.;19(11):1385-96. doi: 10.1111/j.1468-1331.2012.03853.x

@article{3ac8dd0f17c34c37a1969de1ba2f9152,

title = "European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society",

abstract = "Background: Since the publication of the first European Federation of Neurological Societies (EFNS) guidelines in 2005 on the management of restless legs syndrome (RLS; also known as Willis-Ekbom disease), there have been major therapeutic advances in the field. Furthermore, the management of RLS is now a part of routine neurological practice in Europe. New drugs have also become available, and further randomized controlled trials have been undertaken. These guidelines were undertaken by the EFNS in collaboration with the European Neurological Society and the European Sleep Research Society. Objectives: To provide an evidence-based update of new treatments published since 2005 for the management of RLS. Methods: First, we determined what the objectives of management of primary and secondary RLS should be. We developed the search strategy and conducted a review of the scientific literature up to 31 December 2011 (print and electronic publications) for the drug classes and interventions employed in RLS treatment. Previous guidelines were consulted. All trials were analysed according to class of evidence, and recommendations made according to the 2004 EFNS criteria for rating. Recommendations: Level A recommendations can be made for rotigotine, ropinirole, pramipexole, gabapentin enacarbil, gabapentin and pregabalin, which are all considered effective for the short-term treatment for RLS. However, for the long-term treatment for RLS, rotigotine is considered effective, gabapentin enacarbil is probably effective, and ropinirole, pramipexole and gabapentin are considered possibly effective. Cabergoline has according to our criteria a level A recommendation, but the taskforce cannot recommend this drug because of its serious adverse events.",

author = "Diego Garcia-Borreguero and Luigi Ferini-Strambi and Ralf Kohnen and Shaun O'Keeffe and Claudia Trenkwalder and Birgit H{\"o}gl and Heike Benes and Poul Jennum and Markku Partinen and Danyal Fer and Pasquale Montagna and Bassetti, {Claudio L} and Alex Iranzo and Karel Sonka and Anne-Marie Williams",

note = "{\textcopyright} 2012 The Author(s) European Journal of Neurology {\textcopyright} 2012 EFNS.",

year = "2012",

month = nov,

doi = "10.1111/j.1468-1331.2012.03853.x",

language = "English",

volume = "19",

pages = "1385--96",

journal = "European Journal of Neurology",

issn = "1351-5101",

publisher = "Wiley-Blackwell",

number = "11",

}

TY - JOUR

T1 - European guidelines on management of restless legs syndrome

T2 - report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society

AU - Garcia-Borreguero, Diego

AU - Ferini-Strambi, Luigi

AU - Kohnen, Ralf

AU - O'Keeffe, Shaun

AU - Trenkwalder, Claudia

AU - Högl, Birgit

AU - Benes, Heike

AU - Jennum, Poul

AU - Partinen, Markku

AU - Fer, Danyal

AU - Montagna, Pasquale

AU - Bassetti, Claudio L

AU - Iranzo, Alex

AU - Sonka, Karel

AU - Williams, Anne-Marie

PY - 2012/11

Y1 - 2012/11

N2 - Background: Since the publication of the first European Federation of Neurological Societies (EFNS) guidelines in 2005 on the management of restless legs syndrome (RLS; also known as Willis-Ekbom disease), there have been major therapeutic advances in the field. Furthermore, the management of RLS is now a part of routine neurological practice in Europe. New drugs have also become available, and further randomized controlled trials have been undertaken. These guidelines were undertaken by the EFNS in collaboration with the European Neurological Society and the European Sleep Research Society. Objectives: To provide an evidence-based update of new treatments published since 2005 for the management of RLS. Methods: First, we determined what the objectives of management of primary and secondary RLS should be. We developed the search strategy and conducted a review of the scientific literature up to 31 December 2011 (print and electronic publications) for the drug classes and interventions employed in RLS treatment. Previous guidelines were consulted. All trials were analysed according to class of evidence, and recommendations made according to the 2004 EFNS criteria for rating. Recommendations: Level A recommendations can be made for rotigotine, ropinirole, pramipexole, gabapentin enacarbil, gabapentin and pregabalin, which are all considered effective for the short-term treatment for RLS. However, for the long-term treatment for RLS, rotigotine is considered effective, gabapentin enacarbil is probably effective, and ropinirole, pramipexole and gabapentin are considered possibly effective. Cabergoline has according to our criteria a level A recommendation, but the taskforce cannot recommend this drug because of its serious adverse events.

AB - Background: Since the publication of the first European Federation of Neurological Societies (EFNS) guidelines in 2005 on the management of restless legs syndrome (RLS; also known as Willis-Ekbom disease), there have been major therapeutic advances in the field. Furthermore, the management of RLS is now a part of routine neurological practice in Europe. New drugs have also become available, and further randomized controlled trials have been undertaken. These guidelines were undertaken by the EFNS in collaboration with the European Neurological Society and the European Sleep Research Society. Objectives: To provide an evidence-based update of new treatments published since 2005 for the management of RLS. Methods: First, we determined what the objectives of management of primary and secondary RLS should be. We developed the search strategy and conducted a review of the scientific literature up to 31 December 2011 (print and electronic publications) for the drug classes and interventions employed in RLS treatment. Previous guidelines were consulted. All trials were analysed according to class of evidence, and recommendations made according to the 2004 EFNS criteria for rating. Recommendations: Level A recommendations can be made for rotigotine, ropinirole, pramipexole, gabapentin enacarbil, gabapentin and pregabalin, which are all considered effective for the short-term treatment for RLS. However, for the long-term treatment for RLS, rotigotine is considered effective, gabapentin enacarbil is probably effective, and ropinirole, pramipexole and gabapentin are considered possibly effective. Cabergoline has according to our criteria a level A recommendation, but the taskforce cannot recommend this drug because of its serious adverse events.

U2 - 10.1111/j.1468-1331.2012.03853.x

DO - 10.1111/j.1468-1331.2012.03853.x

M3 - Journal article

C2 - 22937989

SN - 1351-5101

VL - 19

SP - 1385

EP - 1396

JO - European Journal of Neurology

JF - European Journal of Neurology

IS - 11

ER -